Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2006-06-27
2006-06-27
Le, Long V. (Department: 1641)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C436S015000, C435S007100, C435S007200, C435S007500, C435S007920
Reexamination Certificate
active
07067321
ABSTRACT:
Several neurodegenerative diseases result from the aggregation of polyglutamine repeat proteins into insoluble neuronal intranuclear inclusions. The invention provides methods with which to study the processes of these diseases, including methods for solubilizing polypeptides containing a polyglutamine repeat sequence, for storing these polyglutamine polypeptides and inhibit their spontaneous aggregation, for making the aggregates of polyglutamine polypeptides, for assaying the extension of existing polyglutamine aggregates, for determining the ability of a chemical compound to inhibit aggregation, and for inhibiting aggregation of polyglutamine polypeptides. The invention further provides materials with which to study these diseases including a synthetic aggregate that have a capability to recruit additional monomeric polyglutamine polypeptides and chemical compounds that inhibit the formation and/or extension of polyglutamine aggregates.
REFERENCES:
Biochem. (1999) 38: 8972 by Harper et al.
Paulson et al. (Neuron 1997 19: 333).
Protein Science 2001 10: 887 By CHen et al.
Cell vol. 90, p. 549.
Perutz, MF, et al., “Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases”, Proc. Nat. Acad. Sci., 91:5355-5358 (1994).
Wetzel, R., “Protein Aggregationin vivo”, in Stability of Protein Pharmaceuticals: Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilization, ed. Ahern, TJ and Manning, MC, Plenum Press, New York, pp. 43-88 (1992).
Wetzel, R., “Mutations and off-pathway aggregation of proteins”, Trends in Biotechnology, 12(5):193-198 (1994).
Wetzel, R., “For protein misassembly, it's the “I” decade”, Cell, 86:699-702 (1996).
Scherzinger, et al., “Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology”, Proc. Natl., Acad., Sci., 96:4604-4609 (1999).
Scherzinger, et al., “Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregatesin vitroandin vivo”, Cell, 90:549-558 (1997).
Heiser, et al., “Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy”, PNAS, 97(12):6739-6744 (2000).
Sharma et al., “Peptide models for inherited neurologic disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions”, FEBS Letters, 456:181-185 (1999).
Ester et al., “Aβ deposition inhibitor screen using synthetic amyloid”, Nature Biotechnology, 15:258-263 (1997).
Esler et al., “Deposition of soluble amyloid-β onto amyloid templates: With application for the identification of amyloid fibril extension inhibitors”, Methods in Enzymology, 309:350-374 (1999).
Bohrmann, et al., “Endogenous proteins controlling amyloid β-peptidepolymerization”, J. Biological Chemistry, 274(23):15990-15995 (1999).
Jao, et al., “Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide”, Amyloid: Int. J. Exp. Clin. Invest., 4:240-252 (1997).
Zagorski, et al., “Methodological and chemical factors affecting amyloid β peptide amyloidogenicity”, Methods in Enzymology, 309:189-204 (1999).
Evans, et al., “Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease”, Proc. Natl. Acad. Sci., 92:763-767 (1995).
LeVine, H, and Scholten, JD, “Screening for Pharmacologic inhibitors of amyloid fibril formation”, Methods in Enzymology, 309:467-476 (1999).
Wood, et al., “Selective Inhibition of Aβ fibril formation”, J. Biological Chemistry, 271(8):4086-4092 (1996).
Zoghbi, HY and Orr, HT, “Polyglutamine diseases: protein cleavage and aggregation”, Current Opinions in Neurobiology, 9:566-570 (1999).
Reddy et al., “Recent advances in understanding the pathogenesis of Huntington's disease”, Trends Neurosci., 22:248-255 (1999).
Cummings, CJ, and Zoghbi, HY, “Fourteen and counting: unraveling trinucleotide repeat diseases”, Human Molecular Genetics, 9(6):909-916 (2000).
Wood et al., “Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E”, Biochemistry, 35:12623-12628 (1996).
Berthelier Valerie
Chen Songming
Wetzel Ronald
Yang Wen
Cheu Jacob
Eisenberg, Esq. Howard
Le Long V.
University of Tennessee Research Foundation
LandOfFree
Polyglutamine repeat sequences does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyglutamine repeat sequences, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyglutamine repeat sequences will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684318